SG Americas Securities LLC Buys 376,623 Shares of Organogenesis $ORGO

SG Americas Securities LLC boosted its stake in Organogenesis (NASDAQ:ORGO) by 199.4% in the fourth quarter, HoldingsChannel reports. The institutional investor owned 565,501 shares of the company’s stock after buying an additional 376,623 shares during the quarter. SG Americas Securities LLC’s holdings in Organogenesis were worth $2,929,000 as of its most recent SEC filing.

A number of other hedge funds have also recently bought and sold shares of the company. Assenagon Asset Management S.A. grew its stake in shares of Organogenesis by 14.0% in the 4th quarter. Assenagon Asset Management S.A. now owns 5,535,334 shares of the company’s stock worth $28,673,000 after acquiring an additional 680,392 shares in the last quarter. PharVision Advisers LLC bought a new position in shares of Organogenesis during the third quarter valued at about $155,000. Quarry LP purchased a new position in Organogenesis during the third quarter worth about $25,000. First Light Asset Management LLC grew its position in Organogenesis by 10.6% in the 3rd quarter. First Light Asset Management LLC now owns 7,497,911 shares of the company’s stock worth $31,641,000 after purchasing an additional 720,748 shares in the last quarter. Finally, Bank of America Corp DE increased its stake in Organogenesis by 27.2% in the 3rd quarter. Bank of America Corp DE now owns 611,685 shares of the company’s stock valued at $2,581,000 after buying an additional 130,875 shares during the last quarter. 49.57% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Organogenesis

In related news, Director Michael Joseph Driscoll purchased 10,000 shares of Organogenesis stock in a transaction dated Monday, March 9th. The stock was bought at an average cost of $2.67 per share, for a total transaction of $26,700.00. Following the completion of the transaction, the director owned 225,707 shares in the company, valued at $602,637.69. This trade represents a 4.64% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. 33.00% of the stock is owned by insiders.

Organogenesis Price Performance

Organogenesis stock opened at $2.24 on Friday. The firm has a 50 day moving average price of $3.21 and a 200-day moving average price of $4.19. The company has a quick ratio of 3.32, a current ratio of 3.62 and a debt-to-equity ratio of 0.04. Organogenesis has a twelve month low of $2.21 and a twelve month high of $7.08. The company has a market capitalization of $288.15 million, a P/E ratio of 28.00 and a beta of 1.48.

Organogenesis (NASDAQ:ORGO) last released its earnings results on Thursday, February 26th. The company reported $0.31 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.21 by $0.10. The business had revenue of $225.61 million during the quarter, compared to the consensus estimate of $172.68 million. Organogenesis had a return on equity of 21.41% and a net margin of 5.32%. As a group, equities analysts predict that Organogenesis will post -0.07 EPS for the current year.

Analyst Ratings Changes

Several equities analysts have commented on ORGO shares. BTIG Research reissued a “buy” rating and set a $8.00 target price on shares of Organogenesis in a research report on Thursday, March 26th. Wall Street Zen raised Organogenesis from a “hold” rating to a “buy” rating in a research report on Sunday, March 8th. Finally, Weiss Ratings upgraded Organogenesis from a “sell (d+)” rating to a “hold (c)” rating in a report on Friday, February 27th. Two analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $8.50.

About Organogenesis

Organogenesis Inc operates as a regenerative medicine company focused on the development, manufacturing and commercialization of therapeutic solutions for wound care, surgical repair and sports medicine. The company’s product portfolio addresses a range of acute and chronic tissue repair needs, leveraging bioengineered skin substitutes, human placental-derived products and other allografts designed to promote healing and reduce scarring. Organogenesis markets its therapies to hospitals, outpatient clinics, wound care centers and other healthcare providers.

Key offerings include Apligraf, a living skin substitute for treatment of diabetic foot ulcers and venous leg ulcers; Dermagraft, a cryopreserved human fibroblast-derived dermal substitute; Grafix, a placental membrane allograft for complex and chronic wounds; and TheraSkin, a cryopreserved human skin allograft used in surgical and reconstructive procedures.